{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:26:19Z","timestamp":1792459579390,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"vor","delay-in-days":68,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior Reports"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ebr.2021.100439","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T06:02:59Z","timestamp":1616479379000},"page":"100439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Antiseizure Medication use in Gastric Bypass Patients and Other Post-Surgical Malabsorptive States"],"prefix":"10.1016","volume":"16","author":[{"given":"Caitlin S.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro A.","family":"Rabinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin M.","family":"Nystrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Britton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun D.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebr.2021.100439_b0005","unstructured":"Overweight & Obesity [Internet]. [cited 2019 Sep 16]. Available from: https:\/\/www.cdc.gov\/obesity\/data\/adult.html."},{"key":"10.1016\/j.ebr.2021.100439_b0010","unstructured":"Estimate of bariatric surgery numbers 2011-2017 [Internet]. [cited 2019 Sep 16]. Available from: https:\/\/asmbs.org\/resources\/estimate-of-bariatric-surgery-numbers."},{"issue":"519","key":"10.1016\/j.ebr.2021.100439_b0015","first-page":"743","article-title":"Impact of obesity on drug prescribing in primary care","volume":"55","author":"Gibbs","year":"2005","journal-title":"Br J Gen Pract"},{"issue":"5","key":"10.1016\/j.ebr.2021.100439_b0020","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s11695-013-1131-8","article-title":"Medication use following bariatric surgery: Factors associated with early discontinuation","volume":"24","author":"Kennedy","year":"2014","journal-title":"Obes Surg"},{"issue":"5","key":"10.1016\/j.ebr.2021.100439_b0025","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1365-2125.2012.04284.x","article-title":"Trends in oral drug bioavailability following bariatric surgery: Examining the variable extent of impact on exposure of different drug classes","volume":"74","author":"Darwich","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ebr.2021.100439_b0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1467-789X.2009.00614.x","article-title":"A systematic review of drug absorption following bariatric surgery and its theoretical implications","volume":"11","author":"Padwal","year":"2010","journal-title":"Obes Rev"},{"issue":"11","key":"10.1016\/j.ebr.2021.100439_b0035","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/obr.12434","article-title":"Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendations","volume":"17","author":"Azran","year":"2016","journal-title":"Obes Rev"},{"issue":"1","key":"10.1016\/j.ebr.2021.100439_b0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","article-title":"Enzyme induction with antiepileptic drugs: Cause for concern?","volume":"54","author":"Brodie","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2021.100439_b0045","series-title":"Adult Short Bowel Syndrome: Nutrition, Medical, and Surgical management","first-page":"17","article-title":"Short bowel syndrome (SBS): classification, underlying causes, and global footprint","author":"Pironi","year":"2018"},{"issue":"8","key":"10.1016\/j.ebr.2021.100439_b0050","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1007\/s11695-017-2762-y","article-title":"Contribution of malabsorption to weight loss after Roux-en-Y gastric bypass: a systematic review","volume":"27","author":"Mahawar","year":"2017","journal-title":"Obes Surg"},{"key":"10.1016\/j.ebr.2021.100439_b0055","doi-asserted-by":"crossref","unstructured":"Andari Sawaya R, Jaffe J, Friedenberg L, K. Friedenberg F. Vitamin, Mineral, and Drug Absorption Following Bariatric Surgery. Curr Drug Metab. 2012;13(9):1345\u201355.","DOI":"10.2174\/138920012803341339"},{"key":"10.1016\/j.ebr.2021.100439_b0060","unstructured":"Le J. Drug Absorption [Internet]. Merck Manual. 2019 [cited 2020 Aug 13]. Available from: https:\/\/www.merckmanuals.com\/professional\/clinical-pharmacology\/pharmacokinetics\/drug-absorption#:~:text=However%2C whether a drug is,Drug Absorption %3A Oral Administration)."},{"issue":"5","key":"10.1016\/j.ebr.2021.100439_b0065","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/bdd.2510160502","article-title":"Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals","volume":"16","author":"Kararli","year":"1995","journal-title":"Biopharm Drug Dispos"},{"issue":"8","key":"10.1016\/j.ebr.2021.100439_b0070","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gut.29.8.1035","article-title":"Measurement of gastrointestinal pH profiles in normal ambulant human subjects","volume":"29","author":"Evans","year":"1988","journal-title":"Gut"},{"issue":"S1","key":"10.1016\/j.ebr.2021.100439_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2167-1052.S1-001","article-title":"Pharmacokinetic Changes Secondary to Roux en Y Gastric Bypass","volume":"01","author":"Giuliano","year":"2012","journal-title":"Adv Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"10.1016\/j.ebr.2021.100439_b0080","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1517\/17425255.2012.722757","article-title":"The effects of gastric bypass surgery on drug absorption and pharmacokinetics","volume":"8","author":"Brocks","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"10.1016\/j.ebr.2021.100439_b0085","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/jcph.65","article-title":"The influence of bypass procedures and other anatomical changes in the gastrointestinal tract on the oral bioavailability of drugs","volume":"53","author":"De Smet","year":"2013","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.ebr.2021.100439_b0090","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1211\/jpp\/61.05.0002","article-title":"Cytochrome P450-mediated metabolism in the human gut wall","volume":"61","author":"Dressman","year":"2009","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"10.1016\/j.ebr.2021.100439_b0095","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0009-9236(98)90177-1","article-title":"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy","volume":"64","author":"Garg","year":"1998","journal-title":"Clin Pharmacol Ther"},{"issue":"23","key":"10.1016\/j.ebr.2021.100439_b0100","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2146\/ajhp100630","article-title":"Pharmacokinetic considerations in Roux-en-Y gastric bypass patients","volume":"68","author":"Smith","year":"2011","journal-title":"Am J Heal Pharm"},{"issue":"6","key":"10.1016\/j.ebr.2021.100439_b0105","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40262-015-0259-1","article-title":"Altered drug disposition following bariatric surgery: A research challenge","volume":"54","author":"Greenblatt","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.ebr.2021.100439_b0110","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s11695-013-0882-6","article-title":"Influence of bariatric surgery on the use and pharmacokinetics of some major drug classes","volume":"23","author":"Yska","year":"2013","journal-title":"Obes Surg"},{"issue":"5","key":"10.1016\/j.ebr.2021.100439_b0115","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2125.1979.tb00996.x","article-title":"Phenytoin absorption in patients with ileojejunal bypass","volume":"7","author":"Kennedy","year":"1979","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.ebr.2021.100439_b0120","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s11695-010-0107-1","article-title":"Reduced Phenytoin levels in an epileptic patient following Roux-En-Y gastric bypass for obesity","volume":"21","author":"Pournaras","year":"2011","journal-title":"Obes Surg"},{"issue":"4","key":"10.1016\/j.ebr.2021.100439_b0125","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/phar.1912","article-title":"Valproate protein binding is highly variable in ICU patients and not predicted by total serum concentrations: A case series and literature review","volume":"37","author":"Riker","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.ebr.2021.100439_b0130","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/phar.1965","article-title":"Clinical importance of monitoring unbound valproic acid concentration in patients with hypoalbuminemia","volume":"37","author":"Dor\u00e9","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ebr.2021.100439_b0135","first-page":"69","article-title":"Use of total and free anticonvulsant serum levels in clinical practice","volume":"21","author":"Rg","year":"1985","journal-title":"Clin Exp Neurol"},{"issue":"3","key":"10.1016\/j.ebr.2021.100439_b0140","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","article-title":"Clinically relevant drug interactions with antiepileptic drugs","volume":"61","author":"Perucca","year":"2006","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.ebr.2021.100439_b0145","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1001\/archneur.1981.00510040066011","article-title":"Dissociation between free and bound phenytoin levels in presence of valproate sodium","volume":"38","author":"Rodin","year":"1981","journal-title":"Arch Neurol"},{"issue":"11","key":"10.1016\/j.ebr.2021.100439_b0150","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1212\/WNL.30.11.1233","article-title":"Interactions of valproic acid with phenytoin","volume":"30","author":"Bruni","year":"1980","journal-title":"Neurology"},{"issue":"D1","key":"10.1016\/j.ebr.2021.100439_b0155","doi-asserted-by":"crossref","first-page":"D608","DOI":"10.1093\/nar\/gkx1089","article-title":"HMDB 4.0: The human metabolome database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ebr.2021.100439_b0160","unstructured":"Novartis. Carbamazepine (tegretol) package insert. East Hanover, New Jersey; 2007."},{"key":"10.1016\/j.ebr.2021.100439_b0165","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2125.2001.01359.x","article-title":"Carbamazepine is not a substrate for P-glycoprotein","volume":"51","author":"Owen","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ebr.2021.100439_b0170","series-title":"Poisoning & Drug Overdose","article-title":"Carbamazepine and Oxcarbazepine","author":"Kearney","year":"2012"},{"issue":"12","key":"10.1016\/j.ebr.2021.100439_b0175","first-page":"557","article-title":"Influence of food on the bioavailability of a carbamazepine slow-release formulation","volume":"35","author":"Retzow","year":"1997","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.ebr.2021.100439_b0180","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2165\/00003495-199345060-00008","article-title":"Felbamate A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy","volume":"45","author":"Palmer","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.ebr.2021.100439_b0185","series-title":"Felbamate (felbatol) [package insert]. Somerset, NJ: Pharmaceuticals MEDA, 2011","year":"2011"},{"key":"10.1016\/j.ebr.2021.100439_b0190","first-page":"17","article-title":"Clinical pharrnacokinetics of gabapentin","volume":"44","author":"Mclean","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.ebr.2021.100439_b0195","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1023\/A:1018951214146","article-title":"A saturable transport mechanism in intenstinal absorption of gabapentin is the underlying cause of lack of proportionality between increase dose and drug levels in plasma","volume":"10","author":"Stewart","year":"1993","journal-title":"Pharm Res"},{"key":"10.1016\/j.ebr.2021.100439_b0200","unstructured":"Pfizer, Inc. Gabapentin (neurotin) package insert. New York, NY; 2009."},{"issue":"9","key":"10.1016\/j.ebr.2021.100439_b0205","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s40262-015-0276-0","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of lacosamide","volume":"54","author":"Cawello","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.ebr.2021.100439_b0210","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1517\/14656566.2012.667803","article-title":"Pharmacotherapy of the third-generation AEDs: Lacosamide, retigabine and eslicarbazepine acetate","volume":"13","author":"Patsalos","year":"2012","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.ebr.2021.100439_b0215","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s13318-012-0093-x","article-title":"Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: Mass balance following intravenous and oral administration","volume":"37","author":"Cawello","year":"2012","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"10.1016\/j.ebr.2021.100439_b0220","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/nyas.12513","article-title":"Advances in epilepsy treatment: Lacosamide pharmacokinetic profile","volume":"1329","author":"Cawello","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ebr.2021.100439_b0225","doi-asserted-by":"crossref","unstructured":"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074\u201382.","DOI":"10.1093\/nar\/gkx1037"},{"issue":"2","key":"10.1016\/j.ebr.2021.100439_b0230","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bcp.12984","article-title":"Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters","volume":"82","author":"Milosheska","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"1_suppl","key":"10.1016\/j.ebr.2021.100439_b0235","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1177\/0883073897012001041","article-title":"Lamotrigine: Pharmacokinetics","volume":"12","author":"Garnett","year":"1997","journal-title":"J Child Neurol"},{"issue":"10","key":"10.1016\/j.ebr.2021.100439_b0240","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.clinthera.2010.09.001","article-title":"Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers","volume":"32","author":"Stockis","year":"2010","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.ebr.2021.100439_b0245","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1527-3458.2007.00004.x","article-title":"Levetiracetam: The profile of a novel anticonvulsant drug-Part I: preclinical data","volume":"13","author":"De Smedt","year":"2007","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.ebr.2021.100439_b0250","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2013.00192","article-title":"Clinical pharmacology and pharmacokinetics of levetiracetam","volume":"4","author":"Wright","year":"2013","journal-title":"Front Neurol"},{"issue":"12","key":"10.1016\/j.ebr.2021.100439_b0255","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","article-title":"Clinical pharmacokinetics of oxcarbazepine","volume":"42","author":"May","year":"2003","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.ebr.2021.100439_b0260","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00044011-200424040-00001","article-title":"Overview of the clinical pharmacokinetics of oxcarbazepine","volume":"24","author":"Flesch","year":"2004","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.ebr.2021.100439_b0265","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1172\/JCI107160","article-title":"Primate biliary physiology. 8. The effect of phenobarbital upon bile salt synthesis and pool size, biliary lipid secretion, and bile composition","volume":"52","author":"Redinger","year":"1973","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ebr.2021.100439_b0270","doi-asserted-by":"crossref","unstructured":"Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs - Best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239\u201376.","DOI":"10.1111\/j.1528-1167.2008.01561.x"},{"key":"10.1016\/j.ebr.2021.100439_b0275","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF00618516","article-title":"Influence of food on absorption of phenytoin in man","volume":"15","author":"Melander","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"issue":"7-8","key":"10.1016\/j.ebr.2021.100439_b0280","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1345\/aph.19355","article-title":"Phenytoin and enteral feedings: Does evidence support an interaction?","volume":"34","author":"Yeung","year":"2000","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.ebr.2021.100439_b0285","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1358\/dot.1999.35.1.522947","article-title":"Pharmacokinetics and metabolism of topiramate","volume":"35","author":"Bourgeois","year":"1999","journal-title":"Drugs of Today"},{"issue":"4","key":"10.1016\/j.ebr.2021.100439_b0290","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/phrs.1997.0124","article-title":"A pharmacological and clinical review on Topiramate, a new antiepileptic drug","volume":"35","author":"Perucca","year":"1997","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ebr.2021.100439_b0295","doi-asserted-by":"crossref","unstructured":"Single-Dose Pharmacokinetics and Effect of Food on the Bioavailability of Topiramate, A Novel Antiepileptic Drug. J Clin Pharmacol 1996;36(10):884\u201391.","DOI":"10.1002\/j.1552-4604.1996.tb04754.x"},{"key":"10.1016\/j.ebr.2021.100439_b0300","doi-asserted-by":"crossref","unstructured":"Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, et al. Valproic acid pathway. Pharmacogenet Genomics. 2013;23(4):236\u201341.","DOI":"10.1097\/FPC.0b013e32835ea0b2"},{"key":"10.1016\/j.ebr.2021.100439_b0305","year":"2003","journal-title":"Depakore ER (divalproex sodium extended release tablets) [package insert]. North Chicago, IL: Abbott Laboratories"},{"issue":"2","key":"10.1016\/j.ebr.2021.100439_b0310","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/03602532.2016.1157600","article-title":"Role of enterohepatic recirculation in drug disposition: cooperation and complications","volume":"48","author":"Malik","year":"2016","journal-title":"Drug Metab Rev"},{"issue":"10","key":"10.1016\/j.ebr.2021.100439_b0315","first-page":"1490","article-title":"Effects of food on valrpoic acid absorption","volume":"38","author":"Hamilton","year":"1981","journal-title":"Am J Hosp Pharm"}],"container-title":["Epilepsy & Behavior Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986421000137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986421000137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:11:39Z","timestamp":1762906299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589986421000137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":63,"alternative-id":["S2589986421000137"],"URL":"https:\/\/doi.org\/10.1016\/j.ebr.2021.100439","relation":{},"ISSN":["2589-9864"],"issn-type":[{"value":"2589-9864","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiseizure Medication use in Gastric Bypass Patients and Other Post-Surgical Malabsorptive States","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebr.2021.100439","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100439"}}